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BACKGROUND: There are conflicting assumptions re-
garding how patients’ preferences for life-sustaining
treatment change over the course of serious illness.
OBJECTIVE: To examine changes in treatment prefer-
ences over time.
DESIGN: Longitudinal cohort study with 2-year follow-
up.
PARTICIPANTS: Two hundred twenty-six community-
dwelling persons age ≥60 years with advanced cancer,
congestive heart failure, or chronic obstructive pulmo-
nary disease.
MEASUREMENTS: Participants were asked, if faced
with an illness exacerbation that would be fatal if
untreated, whether they would: a) undergo high-burden
treatment at a given likelihood of death and b) undergo
low-burden treatment at a given likelihood of severe
disability, versus a return to current health.
RESULTS: There was little change in the overall
proportions of participants who would undergo therapy
at a given likelihood of death or disability from first to
final interview. Diversity within the population regard-
ing the highest likelihood of death or disability at which
the individual would undergo therapy remained sub-
stantial over time. Despite a small magnitude of change,
the odds of participants’ willingness to undergo high-
burden therapy at a given likelihood of death and to
undergo low-burden therapy at a given likelihood of
severe cognitive disability decreased significantly over
time. Greater functional disability, poorer quality of life,
and lower self-rated life expectancy were associated
with decreased willingness to undergo therapy.
CONCLUSIONS: Diversity among older persons with
advanced illness regarding treatment preferences per-
sists over time. Although the magnitude of change is
small, there is a decreased willingness to undergo
highly burdensome therapy or to risk severe disability
in order to avoid death over time and with declining
health status.
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INTRODUCTION
There are two prevailing but contradictory assumptions regard-
ing changes in the treatment preferences of seriously ill older
persons, and these assumptions have different implications for
the provision of end-of-life care. The first of these posits that, as
patients become more ill, they value quality over quantity of life,
such that their preferences are best met by earlier enrollment in
hospice care.
1,2 The second of these assumptions is that as
patients get closer to death, they are more willing to endure the
burden of therapies for the chance of prolonging life,
3 and
therefore desire ongoing access to intensive interventions.
Conflicting data support both of these assumptions. Al-
though several studies have found that the desire to receive
life-sustaining treatment increases with declining health and/
or psychological status,
4,5 several have found no association
between preferences and health status,
6–8 while others have
found an association between declining health status and
decreasing desire for life-sustaining therapy.
9,10 These studies
all share the approach of assessing patients’ preferences for
interventions, without specifying their possible outcomes.
Patients’ preferences, however, are heavily dependent on these
outcomes.
11,12 Moreover, when these outcomes are not explic-
itly identified, patients may make incorrect assumptions about
what the outcomes are, and they may change their preferences
when their misconceptions are corrected.
13
In an earlier study among a cohort of older persons with
advanced illness, we demonstrated that the acceptability of
certain treatment outcomes, described in terms of different
health states, changed over time and in association with
participants’ own health.
14 Although this assessment of pre-
ferences explicitly considered outcomes, it simplified the
assessment by not including trade-offs between treatment
burden and outcome and not including uncertainty, additional
factors that have been shown to influence preferences.
12 The
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495purpose of the current study was to examine changes in
preferences over time among this same cohort by assessing
participants’ willingness to risk the high treatment burden or
adverse outcomes of potentially life-prolonging therapy.
METHODS
Participants
Participants for this study were 226 community-dwelling older
persons with advanced chronic illness. The Human Investiga-
tions Committee of each of the hospitals participating in the
study approved the study protocol, and each participant
provided written informed consent. We screened sequential
charts of persons aged 60 years or older with a primary
diagnosis of cancer, heart failure, or chronic obstructive
pulmonary disease for the primary eligibility requirement:
advanced illness, as defined by Connecticut Hospice
15 or
SUPPORT
16 criteria. Charts were identified according to the
patient’s age and primary diagnosis in subspecialty outpatient
practices and three hospitals, including the VA, in the greater
New Haven area. Of 26 practices approached for participation,
3 (12%) did not permit chart screening. An additional eligibility
criterion was the need for assistance with at least one
instrumental activity of daily living (IADL)
17 because this has
been shown to provide additional prognostic information.
18
Screening and enrollment was stratified by diagnosis to enroll
approximatelyequal numbers of patients with thethreediagnoses.
Of 548 patients identified by chart review, we were able to
screen 470 by telephone to determine need for IADL assistance
and additional exclusion criteria. Exclusion of 108 patients
who were independent in IADLs; of 77 who had cognitive
impairment, as assessed by the Short Portable Mental Status
Questionnaire
19 and EXIT;
20 and of 6 with part-time Connecti-
cut residence left 279 eligible participants. Of these, 2 died
before and 51 refused participation. Nonparticipants did not
differ from participants according to age or gender. Among
eligible patients with heart failure, 8% refused participation,
compared to 19% among patients with cancer and 25% among
patients with chronic obstructive pulmonary disease (P=.02).
Of the 226 initial participants, 8 withdrew after the initial
interview (4%). Of the surviving 124 participants at the end of
the first year, 98 (79%) consented to a second year of
participation, without further withdrawals. Among those com-
pleting the study, ascertainment of data was 90% complete,
and, among the 10% of missing data, 89% was due to the
participant being too cognitively impaired or too ill to partici-
pate in the interview.
Data Collection
Nurse interviewers performed face-to-face interviews with
patients in their homes at least every 4 months for up to
2 years. If the patient had a decline in health status,
determined by a monthly telephone call, the next interview
was scheduled immediately. The subsequent interview was
conducted every 4 months, unless the patient had another
decline. We defined decline in health status as: (1) a new
disability, defined as requiring assistance from another person
or being unable to perform, a basic activity of daily living
(ADL),
21 (2) a prolonged hospitalization (≥7 days) or a hospi-
talization resulting in a discharge to nursing home or rehabil-
itation facility, or (3) introduction of hospice services.
Descriptive and analytic variables included sociodemo-
graphic, health,andpsychosocialstatus measures.Sociodemo-
graphic variables were obtained at the baseline assessment
only; health and psychosocial measures were obtained at each
interview. Sociodemographic variables included age, gender,
ethnicity, education, sufficiency of monthly income,
22 and
marital status. Health status variables included self-rated
health, ADL
21 and IADL
17 disability (each of 7 ADLs and IADLs
scoredas0forindependent,1forrequiring assistance,and2for
unable to perform), self-rated life expectancy, and pain severity
in the last 24 hours. Psychosocial variables included self-rated
quality of life, depression, measured using the 2-item PRIME-
MD,
23 and whether the patient had a living will.
The outcome variables were patients’ treatment preferences
assessed using the Willingness to Accept Life-Sustaining
Treatment instrument (WALT).
24 The WALT, building on a
number of earlier instruments,
25–27 was developed to assess
treatment preferences through the explicit consideration of the
trade-offs involved in the receipt of life-sustaining therapy. This
approach was chosen because standard decision-analytic
approaches to evaluate preferences are difficult for older
persons to complete,
28 demonstrate poor reliability,
29 frequent-
ly lead to illogical responses,
30,31 and may be particularly ill
suited for the elicitation of preferences regarding life-sustaining
treatment.
32,33
Participants were asked to consider an exacerbation of their
illness, which, if left untreated, would result in their death. In
the first scenario, participants were asked to consider the
trade-off of enduring high treatment burden for a given chance
to avoid death. They were asked whether they would want
high-burden therapy if it would return them to current health.
Participants who would choose to have therapy were then
asked whether they wanted therapy as the likelihood of death
versus a return to current health increased. The second and
third scenarios asked participants to consider the trade-off of
risking a severely impaired health state in order to avoid death.
Participants were asked whether they would want low-burden
therapy resulting in either severe physical disability, described
as being bedbound, or severe cognitive disability, described as
not being aware of what is going on around you. Participants
who would choose not to have therapy were then asked
whether they would want therapy as the likelihood of return
to current health versus disability increased.
Clinically meaningful likelihoods: 1, 10, 50, 90, and 99%
chance of death or impaired health state were used. Pie charts
were used to demonstrate these likelihoods to participants. For
each scenario, we determined the highest likelihood of death,
or physical or cognitive disability at which the participant
would want to receive therapy (See the Appendix for the
scenarios as presented to participants).
Data Analysis
We used descriptive statistics to characterize the population.
To provide a simple, unadjusted, population-level description
of the magnitude of changes in preferences, we examined the
distribution of responses to the 3 scenarios at the initial and
final interviews. The final interview was the interview closest to
death or dropout for those who did not complete 2 years of
follow-up. Next, to determine whether ratings changed signifi-
496 Fried et al.: Changes in Life-Sustaining Treatment Preferences JGIMcantly over time and to determine factors associated with
ratings, we utilized generalized linear mixed effects models,
34,35
by implementing repeated measures continuation-ratio models
with inclusion of a patient-level random effect.
36 The resulting
odds ratio is interpreted as the odds of desiring therapy at a
given likelihood as compared to a lower likelihood of death or
disability. We developed separate multivariable models for each
of the 3 scenarios. Independent variables were eligible for
inclusion in each of the multivariable models if they demon-
strated a bivariate association with the outcome at P<.20. To be
included in the final model, the variable needed to maintain P<.10.
In each model, we included time, age, gender, race, and marital
status regardless of bivariate associations. Time was measured in
months. These analyses were carried out using SAS software
(version 9.1), using Proc NLMIXED.
37
RESULTS
Patient Population
Table 1 provides a description of the 226 participants. During
the 2 years of follow-up, 77% of patients with cancer, 43% of
patients with chronic obstructive pulmonary disease, and 46%
of patients with heart failure died. Of the cohort, 68% had at
least 3 interviews and 36% had 5 or more. The median number
of interviews was 2 for patients with cancer, 4 for patients with
heart failure, and 5 for patients with chronic obstructive
pulmonary disease.
Initial and Final Preferences
Comparing the distribution of responses at the first and final
interviews, there was a small decline in the overall proportions
of participants willing to undergo therapy at a given likelihood
of an adverse outcome in each of the 3 scenarios (Fig. 1). At
both the initial and final interview, there was substantial
variability within the population regarding participants’ will-
ingness to undergo therapy. Even at the final interview, 33%
were willing to undergo high-burden therapy despite a 99%
chance of death. However, 14% were unwilling to undergo
high-burden therapy even with a 0% chance of death. Whereas
Table 1. Description of 226 Participants at Baseline
Description
Diagnosis (%)
Cancer 35
COPD 36
CHF 29
Age (years±SD) 73±7
Education (years±SD) 12±3
Race (%)
White 91
African–American 7
Other 2
Women (%) 43
Married (%) 58
Has a living will (%) 53
Self-rated health: excellent/very good/good (%) 36
Self-rated quality of life: best possible/good (%) 64
Depressed (%) 47
Moderate/severe pain (%) 27
≥2 hospitalizations in past year (%) 47
Intensive care unit admission in past year (%) 34
Self-rated life expectancy (%)
<2 years 15
≥2 years 41
Uncertain 44
Figure 1. Proportion of participants who were willing to undergo
either low- or high-burden therapy at a given likelihood of adverse
outcome versus a return to current health. The diamonds represent
participants’ responses at the initial interview, and the squares
represent participants’ responses at the final interview.
497 Fried et al.: Changes in Life-Sustaining Treatment Preferences JGIM31% were willing to undergo low-burden therapy resulting in
severe physical disability at their final interview, only 7% were
willing to undergo low-burden therapy resulting in severe
cognitive disability.
Factors Associated with Changes in Preference
The results of longitudinal models were consistent with the
descriptive results, with small but significant changes in
participants’ preferences over time. The odds of participants’
willingness to undergo high-burden therapy at a given likeli-
hood of death declined by 6% (95% CI 4%–8%) for each month
of observation, demonstrating that participants became less
willing to endure the burden of therapy in order to avoid death
(Table 2). The odds of participants’ willingness to undergo low-
burden therapy at a given likelihood of severe cognitive
disability declined by 3% (CI 1%–5%) for each month of
observation, demonstrating that participants became less
willing to risk cognitive disability to avoid death. Although
there was a trend toward a decline in the odds of participants’
willingness to accept low-burden therapy at a given likelihood
of severe physical disability over time, this did not reach
statistical significance
Worsening in several measures of health and psychosocial
status was associated with decreased willingness to endure
high-burden therapy and/or risk adverse outcome to avoid
death (Table 2). Decline in ADL status was associated with
decreased willingness to endure high-burden therapy, and
worsening quality of life was associated with decreased
willingness to risk severe physical or cognitive disability.
Compared with those who believed their life expectancy was
longer, participants who believed their life expectancy was
<2 years were less willing to risk cognitive disability.
One measure of worsening health status, decline in IADLs,
was associated with an increased willingness to risk disability
to avoid death. Three measures of health status, diagnosis,
pain, and depression, were not associated with preferences,
nor was diagnosis associated with any of the outcomes we
examined.
Compared to men, women were less willing to undergo high-
burden therapy to avoid death. Nonwhite and married partici-
pants were more willing to risk physical and cognitive disability
as compared to white and unmarried participants. Partici-
pants who reported having just enough or not enough money
at the end of the month were less willing to undergo high-
burden therapy and to risk physical disability to avoid death
compared to those who had more than enough
DISCUSSION
In this study of seriously ill older persons followed for up to
2 years, we assessed how participants weighed the burden of
therapy against the desire to avoid death by asking them
whether, faced with an exacerbation of their illness that would
be fatal if left untreated, they would undergo high-burden
therapy at increasing likelihoods of death versus a return to
their current health. We also assessed how they weighed the
desire to avoid adverse functional outcomes against the desire
to avoid death by asking them whether they would undergo
low-burden therapy at increasing likelihoods of severe physical
or cognitive disability versus a return to their current health.
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498 Fried et al.: Changes in Life-Sustaining Treatment Preferences JGIMThe magnitude of change in the overall proportions of
participants who would accept high-burden therapy at a given
risk of death and low-burden therapy at a given risk of
disability was small. Even at their final interview, large
proportions remained willing to accept high-burden therapy
despite a high likelihood of death. Despite its small magnitude,
the change over time was significant. Participants became less
willing to endure a high burden of therapy and less willing to
risk severe cognitive disability to avoid death. In addition,
several indicators of worsening health status, including greater
ADL disability, and lower self-rated life expectancy and quality
of life, were associated with decreased willingness to endure
high-burden treatment and to risk disability.
The results of this study lend support to both prevailing
assumptions regarding the preferences of seriously ill older
persons. Patients’ decreasing willingness over time and with
worsening health state to accept the burdens of therapy and
risk of disability to avoid death supports the notion that, with
advancing illness, patients value quality over quantity of life. In
contrast, the large proportions of patients who desired high-
burden therapy even with a high likelihood of death at their
final interview supports the notion that some patients main-
tain a great willingness to undergo invasive therapies for even
a small chance of returning to their current health. Moreover,
the increased willingness to risk physical disability associated
with declining IADL status suggest that declines in some
domains of health may be associated with changes in how
patients evaluate quality of life, with an increased acceptance
of certain diminished health states.
38,39
The results of this study confirm our earlier findings in this
cohort, assessing attitudes toward different health states
resulting from treatment, that cognitive disability becomes
less acceptable over time and that, for patients experiencing a
decline in their own physical functioning, physical disability
becomes more acceptable.
14 Unlike the earlier study, however,
which showed that physical disability became more acceptable
in the population as a whole, this study suggested that
patients became less willing to risk physical disability. Because
the current study assessed attitudes toward health states
under conditions of uncertainty, which is a strong determinant
of preferences,
40 the differences in the two studies may be a
reflection of increasing risk aversion over time.
The most important finding of the study may be the
persistence in the diversity in preferences over time. This
diversity highlights the danger in making assumptions about
the preferences of older persons with advanced illness. Taken
together with the changes in preferences over time, these
results demonstrate the need to elicit individual preferences
and to reexamine these preferences over the course of a
patient’s illness. Furthermore, to provide care that is respect-
ful of patients’ preferences, systems of end-of-life care must be
able to provide a range of services, incorporating both palliative
and life-sustaining therapies and tailored to the individual
patient.
41
This study also demonstrated that preferences differed
according to sociodemographic characteristics. The large ma-
jority of nonwhite participants were African–American, and the
association between nonwhite race and increased willingness
to risk disability is consistent with literature showing that
African–Americans are generally more willing than whites to
undergo intensive therapies.
42–44 The decreased willingness of
participants reporting lower incomes to undergo high-burden
therapy or risk physical disability to avoid death raises the
question of whether they were concerned about financial
burden. Although relieving emotional and caregiving burden
on loved ones is a central concern for persons at the end of
life,
45–47 less is known about whether patients’ treatment
decisions are influenced by financial considerations. Comple-
tion of a living will was also associated with a decreased
willingness to risk adverse outcomes. Because of their vague
language, living wills frequently cannot be applied to specific
clinical situations.
48 These results suggest that their comple-
tion may serve as a marker for patients’ desire to limit care to
decrease burden and avoid disability, and should serve as a
prompt for a more detailed discussion of patients’ preferences.
Because the study examined the preferences of patients
with advanced illness, missing data are unavoidable. The
largest cause of missing data in the study was mortality. It is
unclear if these data are “missing” in the sense that this term
is traditionally used because these data, along with the data
from participants who became cognitively impaired or more
severely ill, are not meaningful.
49 However, there were also
missing data from participants who dropped out of the study
for other reasons or who failed to consent to a second year of
participation and, therefore, we cannot know whether these
missing data introduce bias into the results. Nonetheless, the
high overall rates of participation and completeness of data
collection among patients who remained in the study suggest
t h a td a t ac o l l e c t i o nw a sa sc o m p l e t ea sp o s s i b l ei nt h i s
challenging population. Because the study population was
predominantly white, the generalizability of the findings is
limited.
Over time, seriously ill older persons retain great diversity in
their willingness to endure burdensome therapy or risk severe
disability to avoid death. Although the magnitude of change is
small, this willingness decreases over time and with changes in
health status. These findings call for the explicit elicitation of
preferences and a highly individualized approach to the care of
patients with advanced illness that has the flexibility to
respond to changes in preferences.
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APPENDIX
Scenario 1
Think about if you were suddenly to get sick with an illness
that would require you to be in the hospital for at least a
month. It would either be that your [CHF, COPD, cancer]
499 Fried et al.: Changes in Life-Sustaining Treatment Preferences JGIMworsened, or you got sick with a different illness. In the
hospital, you would need to have many minor tests, such as
x-rays and blood draws, and you would require more tests,
such as CT scans. You would need major therapies such as
being in the intensive care unit, receiving surgery, or having a
breathing machine. Without the treatment, you would not
survive. If this treatment would get you back to your current
state of health, would you want to have it?
If NO: Question complete.
If YES: Now, what if the doctor told you that there was a 50/
50 chance that it would work and get you back to your current
state of health. If it did not work, you would not survive.
Without the treatment, then you would not survive for certain.
Would you want the treatment?
If NO: Now what if the doctor told you there were a 90%
(99%) chance that it would work and get you back to your
current state of health and a 10% (1%) chance that it would
not. Without the treatment, then you would not survive for
certain. Would you want the treatment?
If YES: Now, what if the doctor told you there was a 10%
(1%) chance that it would work and get you back to your
current state of health and a 90% (99%) chance that it would
not work. Without the treatment, then you would not survive
for certain. Would you want the treatment?
Scenario 2
Think again about if you were suddenly to get sick with an
illness that would require you to be in the hospital for a few
days to a week. It would either be that your [CHF, COPD,
cancer] worsened, or you got sick with a different illness. In the
hospital, you would need to have minor tests, such as x-rays
and blood draws, and therapies such as intravenous anti-
biotics and oxygen. However, this time, imagine that at the end
of the treatment, you would be in a state where you would be
bedbound. You would not be able to get up out of bed to the
bathroom by yourself, and you would need help with all of your
daily activities. Without the treatment, you would not survive.
Would you want the treatment?
If YES: Question complete.
If NO: Now, what if the doctor told you that there was a 50/
50 chance that it would get you back to your current state or
would leave you bedbound. Without the treatment, then you
would not survive for certain. Would you want the treatment?
If NO: Now what if the doctor told you there were a 90%
(99%) chance that it would work and get you back to your
current state of health and a 10% (1%) chance that it would
leave you bedbound. Without the treatment, then you would
not survive for certain. Would you want the treatment?
If YES: Now, what if the doctor told you there was a 10%
(1%) chance that it would work and get you back to your
current state of health and a 90% (99%) chance that it would
leave you bedbound. Without the treatment, then you would
not survive for certain. Would you want the treatment?
Scenario 3
Think again about if you were suddenly to get sick with an
illness that would require you to be in the hospital for a few days
to a week. It would either be that your [CHF, COPD, cancer]
worsened, oryou got sick with a differentillness. In the hospital,
you would need to have minor tests, such as x-rays and blood
draws, and therapies such as intravenous antibiotics and
oxygen. Now imagine that the treatment would leave you in a
state where your mind would not be working, such that you
would not be aware of what was going on around you or be able
to recognize your loved ones. Without the treatment, you would
not survive. Would you want the treatment?
If YES: Question complete.
If NO: Now, what if the doctor told you that there was a 50/
50 chance that it would get you back to your current state or
would leave you unaware. Without the treatment, then you
would not survive for certain. Would you want the treatment?
If NO: Now what if the doctor told you there were a 90%
(99%) chance that it would work and get you back to your
current state of health and a 10% (1%) chance that it would
leave you unaware. Without the treatment, then you would not
survive for certain. Would you want the treatment?
If YES: Now, what if the doctor told you there was a 10%
(1%) chance that it would work and get you back to your
current state of health and a 90% (99%) chance that it would
leave you unaware. Without the treatment, then you would not
survive for certain. Would you want the treatment?
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